Searched for
CIPLA GLOBAL EXPANSION
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Cipla net profit jumps 17.4% to Rs 1,178 crore in Q1FY25Drug maker Cipla reported a 17.4% year-on-year (YoY) jump in net profit to Rs 1,178 crore in Q1FY25, led by strong US, India and South Afri...
- Cipla eyes acquisitions, inorganic partnerships in US marketCipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company a...
- Samina Hamied of Cipla steps down from her executive roleSamina Hamied, executive vice-chairperson of Cipla, announced her decision to step down from her executive role due to personal and family ...
- Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India salesDrug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
- Cipla invests Rs 42 crore in digital tech firm GoApptivCipla boosts investment in GoApptiv with Rs. 42 crore infusion, raising its stake to 22.99%. This marks their third investment in the digit...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- Cipla launches RT-PCR test kit 'ViraGen' in India partnership with Ubio BiotechUmang Vohra, MD and Global CEO, Cipla, said, "Cipla has been working relentlessly to ensure accessibility to treatments in this fight again...
- Cipla inks licensing deal with Belgium's MultiG for distribution of COVID-19 antibody test kit"As part of this agreement, Cipla will be responsible for distribution of the COVID-19 rapid antibody kit that will be manufactured by Mult...
- Cipla not keen on major M&As to expand footprint: CEO Subhanu SaxenaCipla has said it is not "compelled" to go in for major M&As, preferring instead a semi-inorganic route to expand its global footprint.
- Cipla rallies nearly 2%, hits 52-week high on UK expansion plansThe pharma major is expected to invest nearly Rs 1,030 crore over next few years for launch and development of new drugs as part of its glo...
- Cipla to invest upto 100 million pounds in UK as part of expansionThe company will provide high quality affordable medicines to British National Health Service (NHS).
- Cipla inks pact to acquire 51% stake in Yemeni companyAs part of its global expansion, Cipla had completed the buyout of South African pharma firm Cipla Medpro for Rs 2,707 crore last year.
- Cipla acquires 60% stake in Sri Lankan firm; stock up nearly 3%As part of its global expansion, Cipla has been active in acquisitions. Last year, it completed the buyout of South African pharma firm, sa...
- Cipla buys 60% stake in Sri Lankan co for $14 million"The consideration payable for the transaction is $14 million," the filing said, adding that the proposed acquisition was subject to regula...
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...
Load More
